LUNG CANCER HARB ORING HER2 MUTATION :EPIDE MIOLOGI CAL CHARACTE RISTICS AND, s9 \% K' b% M6 F/ U, G% f, b
THERAPE UTIC PERSPECTIVES4 i% X, y5 e$ d3 S' C, `
J. Mazieres, S. Peters O. N; u3 h) E' N4 C6 Y
Introduction: HER2 oncogene is a memb er of the EGFR family, encoding atransmembrane receptor that drives and regulates cell proliferation. HER2 mutations are identified in about 2% of non small cell lung cancer (NSCLC) , mainly located in exon 20, and appear to be critical for lung cancer carcinogenesis . Very scarce data are available to define a clinical profile of the patients harboring HER2 mutated NSCLC. We aimed to study clinic opatholog ical characteristics an d therapeutic
4 D5 D1 C! b* Q* {; [ Coutcomes of patients harboring HER2 mutation in a large European series. Result s:We retrospec tively ide ntified 46 NSCLC patients diagn osed with HER2 exon 20 mut ation. HER2 mutation was mainly exclusive as only one concomitan t KRas mutation was des cribed. Our population was characterized by a median age of 60 yr (31 to 86 yr), a high proportion of women (30 vs. 16 men, 65% ), and of never smokers (24, 52%). All tumors were adenoc arcinomas (two with lepidic features). Half of the patients had stage IV dise ase at the time of diagnosis. HER2 targeted5 x5 M4 L: P/ X' e9 t
treatment was delivered after convention al chemothe rapy. A total of 20 anti-Her2
3 q( H& k7 F8 [ h; d3 n' Z( jtreatments were eval uable. We observed 4 progressive dise ases, 7 disease stabilizations
1 W% i4 s- W) \# W. }and 9 partial resp onses according to RECIST 1.1 (overall response rate ORR = 45% ;$ ^ F: W3 i/ ^1 k! c7 M% `
disease control rate DCR = 80%). Specifica lly, we obse rved a DCR of 92% for K- C, D2 w' K: o$ N
trastuzum ab-based therapie s (n = 14), 100 % for afatinib (n = 3) but no response to
9 p; x4 h9 T) k' y/ c; \9 d/ E6 Tlapatinib (n = 2) and to a multiTKI (n = 1). Median survival was of 68.2 months and5 a7 b; F1 l' S6 L# ? d
22.9 months for respectively early stage and stag e IV patients.2 z4 k1 s' U$ S% V' ^# C. e9 L
Conclusion: This study, the largest to date dedic ated to HER2 mutated NSCLC,
' p, w. ~+ Z# Greinforces the importance of an HER2 screening strategy in lung adenoc arcinomas .
2 S$ j$ s$ y8 q" v+ x. ZHER2-target ed drugs shou ld be tested further, ide ally withi n large collaborative9 x5 `9 ~7 w+ K" M- c
clinicaltrials.# q X& M, e- M: a$ [- ~' e0 l
|
显身卡
